Antibe Therapeutics Inc.
ATE
Kedudukan dalam Saham
#31892
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Harga Saham
$0.21483059
Disegerakkan terakhir: 2024-05-07
Modal Pasaran
$11.13M
Perubahan (1 hari)
0.34%
Perubahan (1 tahun)
-0.36%
Negara
CA
Perdagangan Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
Sejarah pecahan saham untuk Antibe Therapeutics Inc. (ATE)
Saham Antibe Therapeutics Inc. (simbol: ATE) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ATE yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ATE.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ATE yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ATE.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 9 | x285 |
US
|
|
| 7 | x127 |
IE
|
|
| 9 | x162 |
US
|
|
| 2 | x4 |
US
|
|
| 0 | - |
DE
|
